Hologic, Inc. has announced a definitive agreement for its acquisition by funds managed by Blackstone and TPG, valuing the deal at up to $79 per share, which reflects an enterprise value of up to $18.3 billion. The announcement highlights a premium of approximately 46% over Hologic’s closing price on May 23, 2025, just days before media reports revealed potential acquisition talks.
Ram Jagannath, Senior Managing Director at Blackstone, praised Hologic as a global leader in women’s health, commending its reputation for innovation and the significant positive impact its technologies have had on countless patients worldwide. Jagannath expressed his enthusiasm about collaborating with Hologic’s talented workforce and TPG to drive continued innovation and growth.
Stephen P. MacMillan, Hologic’s Chairman, President, and CEO, echoed this sentiment, stating that partnering with Blackstone and TPG will accelerate Hologic’s growth and bolster its ability to provide critical medical technologies globally. The merger is expected to bring immediate value to stockholders and acknowledges the dedication of Hologic’s employees in achieving this milestone.
TPG’s Co-Managing Partner, John Schilling, emphasized the firm’s commitment to healthcare innovation, noting that Hologic represents an excellent opportunity to foster the development of next-generation medical solutions aimed at improving women’s health outcomes.
The transaction is expected to close in the first half of 2026, pending necessary approvals from Hologic’s stockholders and regulatory bodies. Hologic’s Board of Directors has unanimously endorsed the merger and urges shareholders to support the agreement. The acquisition includes substantial investments from a subsidiary of the Abu Dhabi Investment Authority and an affiliate of GIC, ensuring solid financial backing.
Details indicate that each shareholder will receive $76 in cash for every Hologic share held, along with a non-tradable contingent value right (CVR) that could offer up to $3 per share based on future revenue achievements in Hologic’s Breast Health segment.
In light of the transaction, Hologic has canceled its plans to release fiscal guidance for 2026 and will forgo earnings calls while the acquisition is underway. The company is committed to maintaining its headquarters in Marlborough, Massachusetts, and will continue to operate under its established brand.
This merger represents a notable opportunity for Hologic, reinforcing its strategic position in the healthcare market dedicated to advancing women’s health and fostering innovation in medical technologies.